Document:

psnl-ex41_708.htm

Exhibit 4.1

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES 

EXCHANGE ACT OF 1934

 

 

Personalis, Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following summary of the terms of our common stock is based upon our amended and restated certificate of incorporation and our amended and restated bylaws. This summary does not purport to be complete and is subject to, and is qualified in its entirety by express reference to, the applicable provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, and the amended and restated investor rights agreement (the “IRA”). We encourage you to read our amended and restated certificate of incorporation, our amended and restated bylaws, the IRA, and the applicable provisions of the Delaware General Corporation Law (the “DGCL”) for more information.

 

DESCRIPTION OF CAPITAL STOCK 

 

General

 

Our authorized capital stock consists of 210,000,000 shares, all with a par value of $0.0001 per share, of which: 200,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock.

 

Common Stock

 

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution, or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then-outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are duly authorized, validly issued, fully paid, and nonassessable. All authorized but unissued shares of our common stock are available for issuance by our board of directors without any further stockholder action, except as required by the listing standards of Nasdaq. The rights, preferences, and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock

 

Our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of redeemable convertible preferred stock in one or more series and authorize their issuance. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our redeemable convertible preferred stock could adversely affect the voting power of holders of our common stock, and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing a change of control or other corporate action.

 

Warrants

As of December 31, 2019, our outstanding warrants consist of a warrant to purchase 62,096 shares of common stock at an exercise price of $8.052 per share exercisable for seven years from June 28, 2017 and a warrant to purchase 65,502 shares of common stock at an exercise price of $9.16 per share exercisable for seven years from March 22, 2019. 

 

Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws

 

Some provisions of Delaware law, our amended and restated certificate of incorporation, and our amended and restated bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of 

us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.

 

These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.

 

Stockholder Meetings

 

Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors.

 

Requirements for Advance Notification of Stockholder Nominations and Proposals

 

Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.

 

Elimination of Stockholder Action by Written Consent

 

Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting.

 

Staggered Board

 

Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.

 

Removal of Directors

 

Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.

 

Stockholders Not Entitled to Cumulative Voting

 

Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.

 

Delaware Anti-Takeover Statute

 

We are subject to Section 203 of the DGCL, which prohibits persons deemed to be “interested stockholders” from engaging in a “business combination” with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.

 

Choice of Forum

 

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees, or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. Our amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice of forum provisions. It is possible that a court of law could rule that the choice of forum provisions to be contained in our amended and restated certificate of incorporation are inapplicable or unenforceable if they are challenged in a proceeding or otherwise.

 

Amendment of Charter Provisions

 

The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two-thirds of the total voting power of all of our outstanding voting stock.

 

The provisions of Delaware law, our amended and restated certificate of incorporation, and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.

 

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. 

 

 

Exchange Listing

 

Our common stock is currently listed on The Nasdaq Global Market under the symbol “PSNL.”psnl-ex1025_964.htm

                                                                                                                                                                            Exhibit 10.25

 

 

[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. 

 

QUOTATION FOR SUPPLY OF GENETIC ANALYSIS PRODUCTS

Prepared by:

 

 

Illumina, Inc.

5200 Illumina Way

San Diego, CA, 92122-4616, US

 

 

 

Hereinafter referred to as “Illumina”

 

 

 

 

 

Prepared For:

Personalis

Hereinafter referred to as “ Personalis ”

		
	
Quotation Number:
	
[***]

	
Quotation Date:
	
November 19, 2019

	
Expiration Date:
	
December 31, 2020

	
Prepared by:
	
[***]

	
Phone Number:
	
[***]

	
Email:
	
[***]

 

Proposal#      [***]                                       Page 1 of 12

Proposal#[***]Page 2 of 12

I.  CUSTOMER INFORMATION

		
	
Company or Institution Name:
	
Personalis

	
Address:
	
1330 Obrien Dr, Menlo Park, CA, 94025-1436.

II.  PRODUCT & PRICING INFORMATION

Customer receives the following discount on the product families listed below (excludes promotionally priced consumables, software, hardware or new instrument purchases). For the discount to apply, Customer must agree to the following:

	
•
	
This Master Quote, which can be used for multiple purchases, will only be valid until 5:00pm on the expiration date listed on page 1.

	
•
	
All Customer Purchase Orders received by Illumina that include this discounted pricing must be in the quoted currency and reference this quotation.

	
•
	
All discounts will be applied to Illumina's then current list price. Illumina shall at its sole discretion, adjust discount percentages for future products or for any list price adjustments to the products offered on this Quotation.

	
•
	
The pricing and terms of this offer are kept confidential except as needed to execute the purchase.

	
•
	
Discount for consumables applies only to the product families specified in the table herein.

	
•
	
Customer understands that product pricing stated herein is not inclusive of any applicable shipping, freight and/or taxes. Any estimated shipping and freight charges listed on this quotation may differ from actual charges. Any shipping/freight costs will be pre-paid and charged back to Customer. Customer accepts responsibility for any actual incurred shipping/freight costs.

	
Product Family
	
Discount%

	
MiSeq Sequencing Consumables
	
[***]

	
Sample Preparation Consumables
	
[***]

	
SBS and Cluster Generation Sequencing Co
	
[***]

	
Miscellaneous Sequencing Consumables
	
[***]

 

	
Discount Exception

	
Catalog #
	
Product Description
	
Discount

	
20012865
	
NovaSeq 5000/6000 S1 Rgt Kit (100 cyc)
	
[***]

	
20012864
	
NovaSeq 5000/6000 S1 Rgt Kit (200 cyc)
	
[***]

	
20012863
	
NovaSeq 5000/6000 S1 Rgt Kit (300 cyc)
	
[***]

	
20012862
	
NovaSeq 5000/6000 S2 Rgt Kit (100 cyc)
	
[***]

	
20012861
	
NovaSeq 5000/6000 S2 Rgt Kit (200 cyc)
	
[***]

	
20012860
	
NovaSeq 5000/6000 S2 Rgt Kit (300 cyc)
	
[***]

	
20012866
	
NovaSeq 6000 S4 Rgt Kit (300 cyc)
	
[***]

	
20027464
	
NovaSeq 6000 SP Reagent Kit (100 cycles)
	
[***]

	
20027465
	
NovaSeq 6000 SP Reagent Kit (300 cycles)
	
[***]

	
20029137
	
NovaSeq 6000 SP Reagent Kit (500 cycles)
	
[***]

	
20021665
	
NovaSeq Xp 4-Lane Kit
	
[***]

 

Proposal#[***]Page 3 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
MiSeq Sequencing Consumables

	
MS-102-2003
	
MiSeq® Reagent Kit v2 (500 cycle)
	
[***]
	
[***]

	
MS-102-2002
	
MiSeq® Reagent Kit v2 (300 cycle)
	
[***]
	
[***]

	
MS-102-2001
	
MiSeq® Reagent Kit v2 (50 cycle)
	
[***]
	
[***]

	
MS-102-2023
	
MSQ® RGT KT v2 (500 CYC)-20 PK
	
[***]
	
[***]

	
MS-102-3001
	
MiSeq® Reagent Kit v3 (150 cycle)
	
[***]
	
[***]

	
MS-102-3003
	
MiSeq® Reagent Kit v3 (600 cycle)
	
[***]
	
[***]

	
MS-102-2022
	
MiSeq® RGT Kit v2 (300 cycle)-20 PK
	
[***]
	
[***]

	
MS-102-2021
	
MiSeq® RGT Kit v2 (50 cycle) - 20 PK
	
[***]
	
[***]

	
MS-103-1001
	
MiSeq® Reagent Nano Kit v2 (300 Cycles)
	
[***]
	
[***]

	
MS-103-1002
	
MiSeq® Reagent Micro Kit v2 (300 Cycles)
	
[***]
	
[***]

	
MS-103-1003
	
MiSeq® Reagent Nano Kit v2 (500 Cycles)
	
[***]
	
[***]

	
20021681
	
MiSeq FGx Reagent Micro Kit
	
[***]
	
[***]

	
DX-102-1001
	
MiSEQDx CF Clinical SEQ Assay (6 Run)"
	
[***]
	
[***]

	
DX-102-1004
	
MiSeqDx CF 139 Variant Assay (2 Run)"
	
[***]
	
[***]

	
NovaSeq 5000/6000 Sequencing Cons

	
20012865
	
NovaSeq 5000/6000 S1 Rgt Kit (100 cyc)
	
[***]
	
[***]

	
20012864
	
NovaSeq 5000/6000 S1 Rgt Kit (200 cyc)
	
[***]
	
[***]

	
20012863
	
NovaSeq 5000/6000 S1 Rgt Kit (300 cyc)
	
[***]
	
[***]

	
20012862
	
NovaSeq 5000/6000 S2 Rgt Kit (100 cyc)
	
[***]
	
[***]

	
20012861
	
NovaSeq 5000/6000 S2 Rgt Kit (200 cyc)
	
[***]
	
[***]

	
20012860
	
NovaSeq 5000/6000 S2 Rgt Kit (300 cyc)
	
[***]
	
[***]

	
20012866*
	
NovaSeq 6000 S4 Rgt Kit (300 cyc)
	
[***]
	
[***]

	
20027464
	
NovaSeq 6000 SP Reagent Kit (100 cycles)
	
[***]
	
[***]

	
20027465
	
NovaSeq 6000 SP Reagent Kit (300 cycles)
	
[***]
	
[***]

	
20029137
	
NovaSeq 6000 SP Reagent Kit (500 cycles)
	
[***]
	
[***]

	
20021665
	
NovaSeq Xp 4-Lane Kit
	
[***]
	
[***]

	
Sample Preparation Consumables

	
20014279
	
SureCell Whl Trans 3 Pr Kt (2 crtg kt )
	
[***]
	
[***]

	
20014280
	
SureCell Whl Trans 3 Pr Kt (6 crtg kt)
	
[***]
	
[***]

	
20015090
	
CRUK SMP v2 Consortia
	
[***]
	
[***]

	
20015091
	
CEU Consortia
	
[***]
	
[***]

	
20015949
	
TruSeq DNA Idx Kit Pl (96 idx,96 spl)
	
[***]
	
[***]

	
20015960
	
TruSeq DNA Idx Kit Set A (12 idx,24 spl)
	
[***]
	
[***]

	
20015961
	
TruSeq DNA Idx Kit Set B (12 idx,24 spl)
	
[***]
	
[***]

Proposal#[***]Page 4 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
20015962
	
TruSeq DNA PCR-Free LT LPK (24 spl)
	
[***]
	
[***]

	
20015963
	
TruSeq DNA PCR-Free HT LPK (96 spl)
	
[***]
	
[***]

	
20015964
	
TruSeq Nano DNA LT LPK (24 spl)
	
[***]
	
[***]

	
20024144
	
ILMN Free Adptr Blkng Rgnt (12 rxns)
	
[***]
	
[***]

	
20006259
	
TruSeq Custom Amplicon Dx – FFPE QC
	
[***]
	
[***]

	
20006989
	
High Thrghpt TruSeq R Enrch DNA LPK
	
[***]
	
[***]

	
20006994
	
TruSight HLA v1 Box 4 (Post-PCR)
	
[***]
	
[***]

	
20010179
	
TruSight HLA-B Primers v2 Kit
	
[***]
	
[***]

	
20010184
	
TruSight Oncology Library Prep
	
[***]
	
[***]

	
20010185
	
TruSight Oncology DNA Library Prep
	
[***]
	
[***]

	
20010186
	
TruSight Oncology RNA Library Prep
	
[***]
	
[***]

	
20010187
	
TruSight Oncology Enrichment
	
[***]
	
[***]

	
20010188
	
TruSight Tumor 170 Content Set
	
[***]
	
[***]

	
20010190
	
TruSight HLA-DRB Primers v2 Kit
	
[***]
	
[***]

	
20027216
	
Nextera Compatible Unique Dual Idx - D
	
[***]
	
[***]

	
20027215
	
Nextera Compatible Unique Dual Idx - C
	
[***]
	
[***]

	
20027214
	
Nextera Compatible Unique Dual Idx - B
	
[***]
	
[***]

	
20027213
	
Nextera Compatible Unique Dual Idx - A
	
[***]
	
[***]

	
20025895
	
VeriSeq NIPT SMP Prep Kit (24 SMP)
	
[***]
	
[***]

	
20025524
	
Nextera DNA Flex LPK Enrich (96 Spl)
	
[***]
	
[***]

	
20025523
	
Nextera DNA Flex LPK Enrich (16 Spl)
	
[***]
	
[***]

	
20025520
	
Nextera DNA Flex LPK - Small (96 Spl)
	
[***]
	
[***]

	
20025519
	
Nextera DNA Flex LPK - Small (16 Spl)
	
[***]
	
[***]

	
20024586
	
TruSight Oncology UMI Reagents
	
[***]
	
[***]

	
20024145
	
ILMN Free Adptr Blkng Rgnt (48 rxns)
	
[***]
	
[***]

	
20011891
	
Canadian Consortia Inherited Cancer
	
[***]
	
[***]

	
20015965
	
TruSeq Nano DNA HT LPK (96 spl)
	
[***]
	
[***]

	
20020590
	
IDT-TruSeq DNA UD Idx (24 Idx, 96 Spl)
	
[***]
	
[***]

	
20020591
	
IDT-TruSeq RNA UD Idx (24 Idx, 96 Spl)
	
[***]
	
[***]

	
20020594
	
TruSeq Stranded mRNA LP (48 Spl)
	
[***]
	
[***]

	
20020595
	
TruSeq Stranded mRNA LP (96 Spl)
	
[***]
	
[***]

	
20020596
	
TruSeq Strnd Total RNA LP HMR (48 Spl)
	
[***]
	
[***]

	
20020597
	
TruSeq Strnd Total RNA LP HMR (96 Spl)
	
[***]
	
[***]

	
20020598
	
TruSeq Strnd Total RNA LP Gold (48 Spl)
	
[***]
	
[***]

	
20020599
	
TruSeq Strnd Total RNA LP Gold (96 Spl)
	
[***]
	
[***]

Proposal#[***]Page 5 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
20020610
	
TruSeq Strnd Total RNA LP Plant (48 Spl)
	
[***]
	
[***]

	
20020611
	
TruSeq Strnd Total RNA LP Plant (96 Spl)
	
[***]
	
[***]

	
20020612
	
TruSeq Strnd Total RNA LP Globin(48 Spl)
	
[***]
	
[***]

	
20020613
	
TruSeq Strnd Total RNA LP Globin(96 Spl)
	
[***]
	
[***]

	
20020614
	
TruSeq Exome Kit (24 Spl)
	
[***]
	
[***]

	
20020615
	
TruSeq Exome Kit (96 Spl)
	
[***]
	
[***]

	
20020616
	
Nextera Exome Kit (24 Spl)
	
[***]
	
[***]

	
20020617
	
Nextera Exome Kit (96 Spl)
	
[***]
	
[***]

	
20021354
	
TruSeq Neuro Panel 24/48/4
	
[***]
	
[***]

	
20021356
	
TruSeq Neuro Panel 96/288/24
	
[***]
	
[***]

	
20022370
	
IDT for Illumina TruSeq DNA UD Indices
	
[***]
	
[***]

	
20022371
	
IDT for Illumina TruSeq RNA UD Indices
	
[***]
	
[***]

	
20023394
	
TruSight cfDNA UMI HiSeq 2500 Kt(48 Spl)
	
[***]
	
[***]

	
20023395
	
TruSight cfDNA UMI HiSeq 4000 Kt(48 Spl)
	
[***]
	
[***]

	
20015966
	
TruSight® Lymphoma 40 (8 SMP)
	
[***]
	
[***]

	
20015967
	
TruSight® Lymphoma 40 (48 SMP)
	
[***]
	
[***]

	
20015968
	
TruSight® ALL 52 (16 SMP)
	
[***]
	
[***]

	
20015969
	
TruSight® ALL 52 (96 SMP)
	
[***]
	
[***]

	
20015970
	
TruSight® Myeloma 43 (16 SMP)
	
[***]
	
[***]

	
20015971
	
TruSight® Myeloma 43 (96 SMP)
	
[***]
	
[***]

	
20018622
	
TruSight Tumor 170 LPK - Watson
	
[***]
	
[***]

	
20018704
	
Nextera DNA Flex LPK (24 SPl)
	
[***]
	
[***]

	
20018705
	
Nextera DNA Flex LPK (96 SPl)
	
[***]
	
[***]

	
20018706
	
Flex Lysis reagent Kit
	
[***]
	
[***]

	
20018707
	
Nextera DNA CD Idx (24 Idx, 24 SPl)
	
[***]
	
[***]

	
20018708
	
Nextera DNA CD Idx (96 Idx, 96 SPl)
	
[***]
	
[***]

	
20019792
	
TruSeq RNA CD Idx (96 Idx, 96 Spl)
	
[***]
	
[***]

	
20020181
	
TruSeq DNA LP for Enrch (24 Spl)
	
[***]
	
[***]

	
20020182
	
TruSeq DNA LP for Enrch (96 Spl)
	
[***]
	
[***]

	
20020183
	
Exome Panel (45Mb)
	
[***]
	
[***]

	
20020187
	
Nextera DNA LP for Enrch (24 Spl)
	
[***]
	
[***]

	
20020188
	
Nextera DNA LP for Enrch (96 Spl)
	
[***]
	
[***]

	
20020189
	
TruSeq RNA LP for Enrch (48 Spl)
	
[***]
	
[***]

	
20020490
	
TruSeq RNA Enrch (12 enrch)
	
[***]
	
[***]

	
20020492
	
TruSeq RNA Sgl Idx SetA (12 Idx,48 Spl)
	
[***]
	
[***]

Proposal#[***]Page 6 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
20020493
	
TruSeq RNA Sgl Idx SetB (12 Idx,48 Spl)
	
[***]
	
[***]

	
FC-131-1001
	
NXTR® XT IDX Kit (24 IDXS, 96 SMP)
	
[***]
	
[***]

	
RT-402-1001
	
TruSq® Trgtd RNA IDX KtA, 96 IDX 384 SMP
	
[***]
	
[***]

	
FC-132-1001
	
Nextera® Mate Pair Sample PrepKit
	
[***]
	
[***]

	
RT-401-1001
	
TruSeq® Trgtd RNA IDX Kt, 48 IDX 192 SMP
	
[***]
	
[***]

	
IP-202-1024
	
TruSeq® ChIP SMP Prep Kit 48 SMP-Set B
	
[***]
	
[***]

	
IP-202-1012
	
TruSeq® ChIP SMP Prep Kit 48 SMP-Set A
	
[***]
	
[***]

	
AB0007
	
FusionPlex® CTL, for Illumina®
	
[***]
	
[***]

	
FC-121-0202
	
TruSightTM Cancer Sequencing Panel
	
[***]
	
[***]

	
FC-121-0205
	
TruSight Inherited Disease SEQ Panel"
	
[***]
	
[***]

	
FC-130-1010
	
TruSightTM Myeloid Sequencing Panel
	
[***]
	
[***]

	
RT-402-1002
	
TruSq® Trgtd RNA IDX KtB, 96 IDX 384 SMP
	
[***]
	
[***]

	
RT-402-1003
	
TruSq® Trgtd RNA IDX KtC, 96 IDX 384 SMP
	
[***]
	
[***]

	
RT-402-1004
	
TruSq® Trgtd RNA IDX KtD, 96 IDX 384 SMP
	
[***]
	
[***]

	
FC-140-1101
	
TruSite RPD CPTR KT (1INX 8 SMP)
	
[***]
	
[***]

	
FC-140-1102
	
TruSite RPD CPTR KT (2INX 8 SMP)
	
[***]
	
[***]

	
FC-140-1103
	
TruSite RPD CPTR KT (4INX 16 SMP)
	
[***]
	
[***]

	
FC-140-1104
	
TruSite RPD CPTR KT (24 INX 48 SMP)
	
[***]
	
[***]

	
FC-140-1105
	
TruSite RPD CPTR KT (24 INX 96 SMP)
	
[***]
	
[***]

	
FC-140-1106
	
TruSite RPD CPTR KT (96 INX 288 SMP)
	
[***]
	
[***]

	
AB0005
	
FusionPlex® Solid Tumor, for Illumina®
	
[***]
	
[***]

	
FC-131-1096
	
NXTR® XT DNA SMP Prep Kit (96 SMP)
	
[***]
	
[***]

	
SA0045
	
MBC Adapters A41-A48 for Illumina®
	
[***]
	
[***]

	
SA0044
	
MBC Adapters A33-A40 for Illumina®
	
[***]
	
[***]

	
SA0043
	
MBC Adapters A25-A32 for Illumina®
	
[***]
	
[***]

	
SA0042
	
MBC Adapters A17-A24 for Illumina®
	
[***]
	
[***]

	
SA0041
	
MBC Adapters A9-A16 for Illumina®
	
[***]
	
[***]

	
SA0040
	
Archer® MBC Adapters A1-A8 for Illumina®
	
[***]
	
[***]

	
RS-200-0012
	
TruSeq® Small RNA SMP PrepKit v2set A
	
[***]
	
[***]

	
RS-200-0024
	
TruSeq® Small RNA SMP PrepKit v2 set B
	
[***]
	
[***]

	
RS-200-0036
	
TruSeq® Small RNA SMP PrepKit v2 set C
	
[***]
	
[***]

	
RS-200-0048
	
TruSeq® Small RNA SMP PrepKit v2 set D
	
[***]
	
[***]

	
AB0019
	
FusionPlex® Lymphoma, for Illumina®
	
[***]
	
[***]

	
AB0017
	
FusionPlex® Pan-Heme, for Illumina®
	
[***]
	
[***]

	
AB0015
	
FusionPlex® Myeloid, for Illumina®
	
[***]
	
[***]

Proposal#[***]Page 7 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
AB0013
	
FusionPlex® ALL, for Illumina®
	
[***]
	
[***]

	
15027865
	
NX#-TDE1,TGMNT DNA ENZ,24RXN,FINISH REAG
	
[***]
	
[***]

	
15027866
	
NX#-TD,TAGMENT DNA BUFFER,FINISH REAG
	
[***]
	
[***]

	
RS-122-2001
	
Kit, TruSeq RNA SMP Prep Kit-v2, 48,SetA
	
[***]
	
[***]

	
RS-122-2002
	
Kit, TruSeq RNA SMPle Prep Kit-v2
	
[***]
	
[***]

	
AB0011
	
FusionPlex® Heme v2, for Illumina®
	
[***]
	
[***]

	
AB0009
	
FusionPlex® Oncology Research
	
[***]
	
[***]

	
FC-130-1003
	
TruSeq® CTM AMPLCN IDXKit 96 IDX,384 SMP
	
[***]
	
[***]

	
FC-130-1007
	
TruSq® IDX PLT Fixture&Collar Kt 2 Each
	
[***]
	
[***]

	
FC-130-1005
	
TruSeq® Index Plate Fixture Kit
	
[***]
	
[***]

	
FC-130-1006
	
TruSeq CSTM Amplicon FLTRPlate 1 Plate)"
	
[***]
	
[***]

	
RS-200-1001
	
TruSeqTM RNA EPH Reagent Tube
	
[***]
	
[***]

	
FC-131-1024
	
NXTR® XT DNA SMP Prep Kit (24 SMP)
	
[***]
	
[***]

	
FC-121-9999
	
TruSeq® FFPE DNA Library PrepQC Kit
	
[***]
	
[***]

	
OP-101-1001
	
TruSight® Tumor 15 Kit
	
[***]
	
[***]

	
20029226
	
TST One Expanded - Oligos (36 Spl)
	
[***]
	
[***]

	
FC-133-1001
	
NXTR® XT LIB Prep KT PulseNet (96 SMP)
	
[***]
	
[***]

	
OP-101-1002
	
TruSight® Tumor 15
	
[***]
	
[***]

	
OP-101-1004
	
TruSight Tumor 170
	
[***]
	
[***]

	
RH-200-1001
	
VeriSeq NIPT SMP Prep Kit(48 SMP)
	
[***]
	
[***]

	
RH-200-1002
	
VeriSeq NIPT SMP Prep Kit(96 SMP)
	
[***]
	
[***]

	
FC-151-1002
	
TruSeq Methyl Capture EPIC Kit (12 smp)
	
[***]
	
[***]

	
FC-151-1003
	
TruSeq Methyl Capture EPIC Kit (48 smp)
	
[***]
	
[***]

	
20028825
	
TG TruSeq Nano DNA HT SMPPrep Kt 96 SMP
	
[***]
	
[***]

	
FC-141-2007
	
TruSight One Expanded Seq Panel (36 smp)
	
[***]
	
[***]

	
RS-303-1002
	
TruSight RNA Pan-Cancer Panel 48smp-SetA
	
[***]
	
[***]

	
RS-303-1003
	
TruSight RNA Pan-Cancer Panel 48smp-SetB
	
[***]
	
[***]

	
RS-304-1002
	
TruSight® RNA Fusion Panel 48SMP - Set A
	
[***]
	
[***]

	
RS-304-1003
	
TruSight® RNA Fusion Panel 48SMP - Set B
	
[***]
	
[***]

	
20028821
	
TruSight Tumor 170 Kit - NextSeq v2.5
	
[***]
	
[***]

	
20000902
	
SeqLab TruSeq DNA PCR-Free LibraryPrepHT
	
[***]
	
[***]

	
20000903
	
SeqLab TruSeq Nano DNA Library Prep HT
	
[***]
	
[***]

	
20028216
	
TruSight Onco 500 DNA/RNA Kt,NSQ(24 Spl)
	
[***]
	
[***]

	
20028215
	
TruSight Onco 500 DNA/RNA Kt (24 Spl)
	
[***]
	
[***]

	
20028214
	
TruSight Onco 500 DNA Kt, NSQ (48 Spl)
	
[***]
	
[***]

Proposal#[***]Page 8 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
20028213
	
TruSight Onco 500 DNA Kt (48 Spl)
	
[***]
	
[***]

	
20005170
	
TruSight HLA v2 (24 samples Automated)
	
[***]
	
[***]

	
20005718
	
TruSeq Custom Amplicon Kit Dx
	
[***]
	
[***]

	
FC-452-1001
	
ForenSeqTM Human Sequencing Control
	
[***]
	
[***]

	
FC-141-1006
	
TruSight One SEQ Panel(9 SMPles)
	
[***]
	
[***]

	
AB0003
	
FusionPlex® Sarcoma, for Illumina®
	
[***]
	
[***]

	
AB0001
	
FusionPlex® Alk Ret Ros1 v2
	
[***]
	
[***]

	
20032629
	
TST170 Kit-NextSeq v2.5(24spl)+PierianDx
	
[***]
	
[***]

	
20032628
	
TST170 Kit (24 Samples)+PierianDx
	
[***]
	
[***]

	
20032627
	
TSO500 DNA/RNA Kit NextSeq (24)PierianDx
	
[***]
	
[***]

	
20032626
	
TSO500 DNA/RNA Kit (24Spl)+PierianDx
	
[***]
	
[***]

	
20032625
	
TSO500 DNA Kit NextSeq (48Spl)+PerianDx
	
[***]
	
[***]

	
20032624
	
TSO500 DNA Kit (48 samples)+PierianDx
	
[***]
	
[***]

	
FC-141-1007
	
TruSight One SEQ Panel(36 SMPles)"
	
[***]
	
[***]

	
FC-141-1010
	
TrSt-Crd-Sq-Kt(MSQ®,12 spls,v2 Ch)
	
[***]
	
[***]

	
FC-141-1011
	
TrSt-Crd-Sq-Kt(NSQ®,48 spls,Mid OTP)
	
[***]
	
[***]

	
20029551
	
TST Hereditary Cancer – oligos (48 spl)
	
[***]
	
[***]

	
20029550
	
TruSeq Neuro - oligos (48 spl)
	
[***]
	
[***]

	
FC-131-2001
	
NXTR® XT IDX Kt v2 Set A 96 IDXS,384 SMP
	
[***]
	
[***]

	
FC-131-2002
	
NXTR® XT IDX Kt v2 Set B 96 IDXS,384 SMP
	
[***]
	
[***]

	
FC-131-2003
	
NXTR® XT IDX Kt v2 Set C 96 IDXS,384 SMP
	
[***]
	
[***]

	
FC-131-2004
	
NXTR® XT IDX Kt v2 Set D 96 IDXS,384 SMP
	
[***]
	
[***]

	
20029274
	
TG Library Prep Partner Kit
	
[***]
	
[***]

	
FC-142-1001
	
TruSight HLA Seq Panel (24 smp)
	
[***]
	
[***]

	
FC-451-1001
	
ForenSeqTM Index Adapter Fixture
	
[***]
	
[***]

	
20029229
	
TST Cardio - Oligos (48 Spl)
	
[***]
	
[***]

	
20029227
	
TST One - Oligos (36 Spl)
	
[***]
	
[***]

	
SBS and Cluster Generation Sequencing Co

	
FC-401-4003
	
HiSeq® SBS Kit v4 (250 Cycle)
	
[***]
	
[***]

	
FC-402-4023
	
HiSeq® Rapid SBS Kit v2 (500 cycles)
	
[***]
	
[***]

	
FC-402-4021
	
HiSeq® Rapid SBS Kit v2 (200 cycles)
	
[***]
	
[***]

	
FC-402-4022
	
HiSeq® Rapid SBS Kit v2 (50 cycles)
	
[***]
	
[***]

	
GD-401-3001
	
TruSeq® SR Cluster Kit v3 – cBotTM - HS
	
[***]
	
[***]

	
PE-401-3001
	
TruSeq® PE Cluster Kit v3 – cBotTM - HS
	
[***]
	
[***]

	
FC-401-3001
	
TruSeq SBS KIT v3 - HS (200 CYCLES)
	
[***]
	
[***]

Proposal#[***]Page 9 of 12

	
Catalog #
	
Product Description
	
List Price
(USD)
	
Customer Price
(USD)

	
FC-401-3002
	
TruSeq SBS KIT v3 - HS (50 CYCLES)
	
[***]
	
[***]

	
FC-401-4002
	
HiSeq® SBS Kit v4 (50 Cycle)
	
[***]
	
[***]

	
PE-402-4002
	
HiSeq® Rapid PE Cluster Kit v2
	
[***]
	
[***]

	
GD-402-4002
	
HiSeq® Rapid SR Cluster Kit v2
	
[***]
	
[***]

	
GD-401-4001
	
HiSeq® SR Cluster Kit v4 – cBotTM
	
[***]
	
[***]

	
20006992
	
High Throughput HiSeq SBS Kit (150 cyc)
	
[***]
	
[***]

	
20006991
	
High Throughput HiSeq PE Cluster Kit
	
[***]
	
[***]

	
PE-401-4001
	
HiSeq® PE Cluster Kit v4 – cBotTM
	
[***]
	
[***]

	
15056112
	
HiSeq® Rapid SBS Kit - FunnelBottle Caps
	
[***]
	
[***]

	
15037576
	
HiSeq® Flowcell Gaskets 4 Pack
	
[***]
	
[***]

	
SBS and Cluster Generation Sequencing Co

	
DX-502-1003
	
Index Adapter Replacement Caps
	
[***]
	
[***]

	
FC-901-1003
	
KIT,BRIDGE MANIFOLD,CLUSTER STATION
	
[***]
	
[***]

	
FC-800-1001
	
TruSeq® Nano DNA Accessory Kit
	
[***]
	
[***]

	
PE-121-1003
	
TruSEQ Dual IDX SEQ PRMR Kit, Paired End
	
[***]
	
[***]

	
FC-121-1003
	
TruSEQ Dual IDX SEQ PRMR Kt, Single Read
	
[***]
	
[***]

	
FC-110-3001
	
PhiX CONTROL V3 KIT
	
[***]
	
[***]

	
GD-304-2001
	
TruSq v2 cBot Multi-PRMR Re-Hybrdztn Kt
	
[***]
	
[***]

	
SY-401-2015
	
KIT,CBOT MANIFOLD,HiSEQ
	
[***]
	
[***]

	
GD-403-4001
	
HSQ® Multi-PRMR Rehybridization Kit v4
	
[***]
	
[***]

	
20015892
	
HT1 Buffer
	
[***]
	
[***]

	
20012552
	
MiSeqDx Reagent Kit v3
	
[***]
	
[***]

	
20005160
	
cBot 2 Barcoded Strip Tubes (8 well)
	
[***]
	
[***]

	
15073345
	
Streck cell free DNA BCT (CE)
	
[***]
	
[***]

	
GD-310-1001
	
HSQ® 3k/4k cBot Multi-PRMR ReHYBRID Kit
	
[***]
	
[***]

	
MS-102-9999
	
MiSeq® Disposable Wash Tubes
	
[***]
	
[***]

	
GD-404-1001
	
HiSeq® Rapid Rehybridization Kit
	
[***]
	
[***]

	
CT-403-2001
	
HiSeq® Rapid Duo cBotTM SampleLoading Kit
	
[***]
	
[***]

	
FC-110-3002
	
NextSeqTM PhiX Control Kit
	
[***]
	
[***]

* Fixed Price is active for this material.
Post Pricing Message: Payment Terms for the account is Net 60

III.  CONDITIONS OF SALE

By submitting an order, Customer accepts and agrees that the Terms and Conditions is the sole and exclusive agreement between Customer and Illumina with respect to the Illumina products and/or services as described above and accepts all other terms of this quotation.
NOTWITHSTANDING THE FOREGOING, IF ILLUMINA AND CUSTOMER HAVE ENTERED INTO A VALID AND ENFORCEABLE AGREEMENT GOVERNING THE ILLUMINA PRODUCTS AND/OR SERVICES DESCRIBED ABOVE, THE ORDER OF PRECEDENCE BETWEEN THE AGREEMENT AND THE TERMS AND CONDITIONS SHALL BE AS FOLLOWS: IN THE EVENT OF A CONFLICT 

Proposal#[***]Page 10 of 12

BETWEEN THE TERMS OF THE AGREEMENT AND THE TERMS AND CONDITIONS, OR IF THE AGREEMENT INCLUDES ADDITIONAL TERMS NOT ADDRESSED IN THE TERMS AND CONDITIONS, THE AGREEMENT SHALL GOVERN WITH RESPECT TO SUCH TERMS.
Illumina does not supply plastics such as microplates or pipette tips for use in the listed assays and these are not included in the consumables pricing provided; however, as a result of the highly multiplexed nature of all assays, plastics alone contribute minimally to the final cost.

Customer and Illumina agree as follows:

	
•
	
Customer’s purchase of the products referenced in this Quotation is not conditioned on future performance characteristics or applications, whether or not realized.

	
•
	
Unless otherwise agreed by Illumina in writing, Illumina will not assist Customer in developing, testing, or validating unsupported applications.

	
•
	
Illumina will not replace any consumables or reagent kits if the cause of any performance failure is due to unsupported applications.

	
•
	
Illumina is unable to provide any assurances or guarantee that the performance of the products referenced in this Quotation will match published specifications when used for unsupported applications.

IV.  SHIP HOLD

In cases where this Quotation does not include a pre-defined ship schedule, the following ship hold terms shall apply:

	
•
	
All orders must have a defined ship schedule. The initial ship date must be no later than three (3) months from the date the purchase order is received by Illumina (as provided in the Order Confirmation) and the entire order must be shipped complete within twelve (12) months from Illumina’s receipt of the purchase order.

	
•
	
Any exceptions to these ship hold terms must be agreed to in writing by Illumina and the Customer must pre-pay at least fifty percent (50%) of the purchase order amount of the affected shipments.

	
•
	
Customers may request two (2) shipment delays for any single purchase order. The total months of delayed shipment for shipments associated with a single purchase order shall not exceed six (6) months.

	
•
	
If Customer has requested a delayed shipment, Illumina reserves the right to change the lead time necessary to initiate Customer’s first shipment (which may be longer than the lead time quoted at the time of the order placement).

	
•
	
If Customer cannot take shipment in accordance with these terms, Illumina reserves the right to cancel the order in its entirety without any liability to the Customer.

V.  HOW TO ORDER

RUO & DX Goods, Instruments and Warranty Coverage (including BlueGnome)

	
For all consumable orders:

	
For all other orders:

Please submit your institutional Purchase Order and a complete copy of this quotation to the attention of:

Illumina Customer Service

customerservice@illumina.com

Phone: +1.858.202.4566
Toll Free: +1.800.809.ILMN (4566)
Fax: +1.858.202.4766

	
Please submit your order online through MyIllumina
(http://my.illumina.com).

	
 

VI.  EXPIRATION OF OFFER

The offer contained in this document is revocable at the sole discretion of Illumina if not executed by Customer and a purchase order received by Illumina before 5:00 pm Pacific Time on the expiration date shown on page 1 of this quotation.

Proposal#[***]Page 11 of 12

Terms and Conditions of Sale

http://www.illumina.com/content/dam/illumina-marketing/documents/terms-conditions/united-states/usa-terms-and-conditions-of-sale- general.pdf. Additionally, if Customer is purchasing Illumina professional consulting services as relate to instruments, Customer environment or workflows (in all cases, excluding instrument warranty services) ("Professional Services"), Customer agrees such Professional Services are exclusively governed by the Terms and Conditions - Services (Professional Services) located here: http://www.illumina.com/content/dam/illumina-marketing/ documents/company/terms-and-conditions-services.pdf

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]